Klaas Zuideveld

CEO at TECregen

Speaker

Klaas Zuideveld is Chief Executive Officer of TECregen, a Basel-based biotechnology company developing immuno-rejuvenation therapies through thymus regeneration to restore immune competence in ageing, cancer, and immunocompromised patients. Under his leadership, TECregen is advancing a pipeline of tissue-targeted cytokine therapeutics and preparing its lead programme for clinical development.

Klaas brings more than 20 years of international experience in drug development, commercialisation, and company building. Across the pharmaceutical value chain, he has led programmes contributing to seven Investigational New Drug applications and nine global drug approvals, including Victoza, Xyzal, Avastin, and Ocrevus, and has overseen the development of three companion diagnostics. He has held senior leadership roles at Roche, Mosaic Biomedicals, Therachon, Caris Life Sciences, and most recently served as CEO of Versameb. Klaas holds a PhD in Pharmacology and Mathematics from Leiden University and is focused on advancing innovative therapies in immunology and regenerative medicine for areas of high unmet need.